NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Domain Associates’

9 April 2014

Delphi Ventures leads new funding round for Sequent Medical

brain_lrg Delphi Ventures has recommitted to portfolio company Sequent Medical by leading a $20m Series D financing round.

12 February 2014

VC backed Cadence Pharmaceuticals sells for $1.3bn

NYSE-listed pharmaceuticals company Mallinckrodt has agreed to acquire VC-backed Cadence Pharmaceuticals for $1.3bn.

22 January 2014

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

dna Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

17 December 2013

Amgen Ventures joins KPCB, others backing $38.5m Series B for drug developer Atara

Thrasos Therapeutics kidney - AltAssets Private Equity News Amgen Ventures is among the new investors committing capital to drug development company Atara Therapeutics as part of a $38.5m Series B financing round.

3 December 2013

Molecular diagnostics company Xagenic raises $20m Series B

Panasonic HealthcareToronto-based molecular diagnostics company Xagenic has secured $20m in a Series B round led by new investor Domain Associates.

14 November 2013

Insulin pump maker Tandem Diabetes Care surges after IPO

stock brokerage market share listed Venture capital-backed Tandem Diabetes Care surged after its IPO on the Nasdaq exchange, which valued the medical devices company at $15 per share.

9 October 2013

Venture-backed medical device maker Tandem Diabetes files for $100m IPO

Tandem Diabetes pump Venture capital-backed insulin pump maker Tandem Diabetes has filed to raise $100m through an IPO on the Nasdaq Global Market.

27 August 2013

Syndax Pharmaceuticals raises $26.6m Series B round from healthcare VCs

US-based Syndax Pharmaceuticals has secured a $26.6m Series B financing from investors including healthcare-focused venture capital firms Domain Associates, MPM Capital, Forward Ventures and Russia’s RusnanoMedInvest.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

dna RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

29 July 2013

Domain Associates and Rusnano back ReVision Optics’ $55m round

life science test tube_sq Venture capital firm Domain Associates said its portfolio ReVision Optics has raised $55m in a funding round which was backed by its partner Rusnano.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014